Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort

These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma. Further trials are warranted to study combination therapies and drug resistance mechanisms.